.webp)
1. Day J H et al. Onset of action, efficacy, and safety of a single dose of fexofenadine hydrochloride. Ann Allergy Asthma Immunol. 1997.79;533-540
2. Smith SM et al. Fexofenadine: biochemical, pharmacokinetic and pharmacodynamic properties and its unique role in allergic disorders. Expert Opinion on Drug Metabolism & Toxicology. 2009.5(7);813-822
3. Mark E et al. Efficacy and tolerability of 2nd and 3rd gen antihistamines. ANNALS OF ALLERGY, ASTHMA & IMMUNOL. 2010.104;518–522.
4. Fein MN et al. CSACI position statement_Newer generation H1-antihistamines (3rd generation) are safer than first-generation H1-antihistamines. Allergy Asthma Clin Immunol. 2019.15(61);1-6.
5. Anne K et al. Second-and third-generation antihistamines. DERMATOLOGIC THERAPY. 2000.13;327-336.
6. Thomas B et al. Next generation antihistamines therapeutic rationale accomplishments and advances. Expert Opinion on Investigational Drugs. 2002.11(6);807-817.
7. Company data on file.
8. 식품의약품안전처. 알레그라정120밀리그람(펙소페나딘염산염) 제품정보. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetailCache?cacheSeq=199801016aupdateTs2024-03-25%2018:18:26.0b (Last accessed in Jun 05, 2024)
9. U.S. FDA. Home > About FDA > FDA Organization > Center for Drug Evaluation and Research | CDER > Prescription to Over-the-Counter (OTC) Switch List. Available at: https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/prescription-over-counter-otc-switch-list (Last accessed Jun 05, 2024)
10. L. Cecchi L, D’Amato G, Annesi-Maesano I. External exposome and allergic respiratory and skin diseases. J Allergy Clin Immunol 2018, 141:846-857
11. Ellis AK, et al. Effect of fexofenadine hydrochloride on allergic rhinitis aggravated by air pollutants. ERJ Open Research. 2021;7(2):00806-2020.